Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05642572 | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | recruiting | Phase 2 | 66 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06003556 | PSMA-Guided Ablation of the Prostate(P-GAP) | recruiting | Phase 2 | 138 | University of AlbertaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06540872 | Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer(MI-CISDIR) | recruiting | Phase 2 | 30 | Universität MünsterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06770452 | HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients | recruiting | Phase 2 | 133 | Zhejiang UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07483554 | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors | recruiting | Phase 2 | 389 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623577 | Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases | recruiting | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06228053 | Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer(SYNERGY-201) | recruiting | Phase 2 | 53 | Syntrix Biosystems, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 80 | MacroGenicsINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT06731413 | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 40 | Virginia Commonwealth UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05933239 | Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients(MAGMA) | recruiting | Phase 2 | 20 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07036380 | MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma(TACTIC) | recruiting | Phase 2 | 75 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617753 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2(DUAL-OV-CAR-NK) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC(RAISE) | recruiting | Phase 2 | 44 | ETOP IBCSG Partners FoundationNETWORK | 5 | May 29, 2026 | clinicaltrials |
| NCT06485778 | A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma | recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy(FASCINATE-N) | recruiting | Phase 2 | 716 | Fudan UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT07452601 | Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC | recruiting | Phase 2 | 90 | Tang-Du HospitalOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07483359 | Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus(CONV3RSION) | recruiting | Phase 2 | 38 | First Hospital of China Medical UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06648096 | Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)(AFAN) | recruiting | Phase 1 / Phase 2 | 25 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT04982653 | Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy | recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05620771 | Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | recruiting | Phase 2 | 200 | Northwestern UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06631092 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 28 | NEC Bio B.VINDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT06949215 | 68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision(NYCRCCL) | recruiting | Phase 2 | 70 | Peking Union Medical College HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06974370 | Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial(ACTION-Brain) | recruiting | Phase 2 | 45 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06998342 | MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer(MOHSAHRTSS) | recruiting | Phase 2 | 24 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07249372 | DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer | recruiting | Phase 2 | 37 | NYU Langone HealthOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07375316 | A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy | recruiting | Phase 2 | 120 | Guangdong Association of Clinical TrialsOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | recruiting | Phase 2 | 280 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06067438 | Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | recruiting | Phase 2 | 90 | OHSU Knight Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | recruiting | Phase 1 / Phase 2 | 307 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06954480 | Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer(DIAMOND) | recruiting | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06963905 | Saci Nivo Rela for TNBC(SIMONE) | recruiting | Phase 1 / Phase 2 | 60 | Yale UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07023432 | Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) | recruiting | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07325539 | LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC(LIGHT) | recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07493668 | Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy(FLEX-HCC) | recruiting | Phase 2 | 80 | CHA UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07601178 | QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer | recruiting | Phase 2 | 34 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06053658 | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06504147 | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | recruiting | Phase 2 | 114 | Oncoinvent Solutions ASINDUSTRY | 6 | May 20, 2026 | clinicaltrials |
| NCT06860815 | Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer | recruiting | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07205731 | Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma(SAFE ESO) | recruiting | Phase 2 | 95 | University Hospital, Clermont-FerrandOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07598955 | Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma(SELECT-NK-THYM) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06502691 | [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | May 19, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 3, 2026source: clinicaltrials